AUTL News and Press, Autolus Therapeutics plc From 06/16/23

At the highest dose 4 out of 4 PTCL patients achieved a response using the original manufacturing process (Process A) Ongoing complete metabolic responses in 2 out of 4 patients at 15 and 18-months post-dosing at the highest dose tested Presence of CAR T cells in the lymph nodes of patien...

2023-06-14 09:39:38 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Unless you regularly invest in or research penny stocks it’s likely you aren’t familiar with most companies in the space. These penny stock picks aren’t household names...

LONDON, June 06, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, has posted notice of its Annual General Meeting (AGM) to shareholders (the "Notice"), which can be viewed and ...

2023-06-02 07:51:13 ET Autolus Therapeutics ( NASDAQ: AUTL ) added ~7% pre-market Friday after announcing Phase 2 data for its CAR T cell therapy obe-cel (AUTO1) will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting. As previously disclose...

76% of patients treated with obe-cel in the FELIX study achieved a response (CR/CRi), primary endpoint has been met based on previously communicated interim analysis Potential best in class tolerability, with very low levels of high-grade CRS and ICANS Robust and reliable manufacturing ...

LONDON, May 22, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will hold an analyst call to highlight data at the 2023 American Society of Clinical On...

2023-05-15 13:13:19 ET Gainers: Ohmyhome Limited ( OMH ) +169% . NeoGames ( NGMS ) +112% . GSI Technology ( GSIT ) +36% . Vaxart ( VXRT ) +34% . WiSA Technologies ( WISA ) +35% . Scilex Holding Company ( SCLX ) +31% ....

LONDON, May 12, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces that the abstract for the pivotal Phase 2 FELIX study of obecabtagene autoleucel (obe-cel) in r...

2023-05-07 07:20:08 ET Autolus Therapeutics plc (AUTL) Q1 2023 Earnings Conference Call May 4, 2023 08:30 AM ET Company Participants Alexandra Deschner - IR, Consultant Christian Itin - CEO Lucinda Crabtree - CFO Conference Call Participants Mara Gold...

2023-05-04 07:25:53 ET Autolus Therapeutics press release ( NASDAQ: AUTL ): Q1 GAAP EPS of -$0.23 beats by $0.04 . Cash and cash equivalents and restricted cash at March 31, 2023, totaled $343.4 million, as compared to cash of $382.8 million at December 31, 2022. ...